Arrowstreet Capital’s Inhibrx INBX Stock Holding History

Arrowstreet Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,003	Closed	-$202K	–	1918
2025 Q3	$202K	Buy	+6,003	New	+$148K	﹤0.01%	1796

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital's INBX Position: Q4 2025 in Review

Arrowstreet Capital sold out of Inhibrx (INBX) in Q4 2025, closing a stake of 6,003 shares — an estimated $202K sold.

Arrowstreet Capital first reported a position in INBX in Q3 2025 and held it in 1 quarter. The position peaked at $202K in Q3 2025. 138 funds tracked by Wall St. Rank hold INBX as of Q4 2025.

Arrowstreet Capital reported no remaining Inhibrx position as of Q4 2025 after selling out during the quarter.
Arrowstreet Capital sold 6,003 Inhibrx shares in Q4 2025, an estimated $202K.
Arrowstreet Capital first reported a position in Inhibrx in Q3 2025 and held it in 1 quarter.
Arrowstreet Capital's Inhibrx position peaked at $202K in Q3 2025.
138 funds tracked by Wall St. Rank held Inhibrx as of Q4 2025.

Based on Arrowstreet Capital's 13F filing for Q4 2025, filed 13 Feb 2026.